Pamrevlumab and idiopathic pulmonary fibrosis

The Lancet Respiratory Medicine in conversation with - A podcast by The Lancet Group

Categories:

Education

Dr. Luca Richeldi discusses a trial looking at pamrevlumab, an anti-connective tissue growth factor therapy for the treatment of idiopathic pulmonary fibrosi Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv